NCT04108247
A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC treatment 1 unknown_status NCT02552121
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors treatment 1 / 2 completed NCT02001623
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors treatment 1 / 2 completed NCT04615845
Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) No drug interventions treatment 1 terminated NCT03690141
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer treatment 2 terminated NCT01020305
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer treatment 1 / 2 terminated NCT01450683
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy treatment 2 terminated NCT02200614
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer treatment 3 completed NCT04704505
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) treatment 2 recruiting NCT05633160
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) No drug interventions treatment 1 / 2 recruiting NCT01637402
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer treatment 2 completed NCT01540071
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer treatment 2 completed NCT04580485
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors treatment 1 completed NCT01120470
OGX-427 in Castration Resistant Prostate Cancer Patients treatment 2 completed NCT01995058
Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer treatment 2 terminated NCT02384382
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) treatment 2 completed NCT01522443
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer treatment 3 terminated NCT01646684
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer treatment 1 completed NCT02833883
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer treatment 1 completed NCT03473925
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) treatment 2 completed NCT05445882
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer treatment 2 withdrawn NCT01605227
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 treatment 3 completed NCT02502994
Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC No drug interventions treatment 1 unknown_status NCT05919329
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy diagnostic 4 recruiting NCT05057013
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours No drug interventions treatment 1 / 2 recruiting NCT06141993
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials No drug interventions Not Available Not Available recruiting NCT06636123
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy No drug interventions treatment 1 not_yet_recruiting NCT05256381
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors treatment 2 active_not_recruiting NCT06329830
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer treatment 1 / 2 withdrawn NCT03522064
Bipolar Androgen Therapy + Carboplatin in mCRPC treatment 2 recruiting NCT06321679
Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone No drug interventions Not Available Not Available recruiting NCT03506997
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer treatment 2 recruiting NCT01634061
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients treatment 1 completed NCT05188911
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial Not Available Not Available unknown_status NCT06193993
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients treatment 1 active_not_recruiting NCT02429193
Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA treatment 2 completed NCT05081193
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer treatment 2 recruiting NCT04028388
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer treatment 2 completed NCT04549207
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer treatment 4 active_not_recruiting NCT03629756
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies treatment 1 completed NCT06227156
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer treatment 2 recruiting NCT05502315
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer treatment 2 recruiting NCT01106352
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) treatment 1 / 2 completed NCT05084859
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors treatment 1 terminated NCT04567875
Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma No drug interventions Not Available Not Available unknown_status NCT03815942
VAccination in Early and ADvanced Prostate caNCEr treatment 1 / 2 unknown_status NCT04060342
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma treatment 1 terminated NCT03700099
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide treatment 2 active_not_recruiting NCT03554317
COMbination of Bipolar Androgen Therapy and Nivolumab treatment 2 completed NCT04222634
Metastasis-directed Therapy in Castration-refractory Prostate Cancer No drug interventions treatment Not Available active_not_recruiting NCT03305224
The Combination Therapy With Ra-223 and Enzalutamide treatment 2 unknown_status NCT03672396
Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer No drug interventions health_services_research Not Available completed NCT01487863
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer basic_science 2 completed NCT03696186
Selective Treatment According to Molecular Subtype of Prostate Cancer treatment 2 unknown_status NCT04541225
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors No drug interventions treatment 1 terminated NCT02346526
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer treatment 2 completed NCT01703065
Cabozantinib in Men With Castration-Resistant Prostate Cancer treatment 2 terminated NCT04781374
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 withdrawn NCT02012920
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer treatment 2 completed NCT01338831
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer No drug interventions treatment 1 completed NCT01543776
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer treatment 2 completed NCT03170960
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors treatment 1 / 2 active_not_recruiting NCT03869762
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. treatment 2 terminated NCT03569280
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients treatment 1 completed NCT04962880
HRR Prevalence in LatAm PROSPECT Study No drug interventions Not Available Not Available completed NCT03136640
ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer treatment 1 completed NCT02207504
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer treatment 1 completed NCT03356912
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy supportive_care 2 unknown_status NCT02025010
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer treatment 2 active_not_recruiting NCT03878823
Safety and Pharmacokinetics of ODM-209 No drug interventions treatment 1 / 2 completed NCT06343038
Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study treatment 1 recruiting NCT03601143
Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients No drug interventions Not Available Not Available recruiting NCT03934164
Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO No drug interventions Not Available Not Available recruiting NCT01487902
The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer No drug interventions treatment 2 unknown_status NCT05437679
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System No drug interventions Not Available Not Available terminated NCT03927287
Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer No drug interventions Not Available Not Available completed NCT03177551
Predictive Nomogram of CRPC No drug interventions Not Available Not Available unknown_status NCT03734653
Testosterone Therapy in Castration Resistant Prostate Cancer treatment 0 active_not_recruiting NCT02578797
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study treatment 1 completed NCT02066961
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer No drug interventions Not Available Not Available completed NCT04232761
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone Not Available Not Available completed NCT04090528
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer treatment 2 active_not_recruiting NCT00974311
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy treatment 3 completed NCT03652493
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway treatment 2 terminated NCT02054793
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) treatment 1 / 2 withdrawn NCT05607693
A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects treatment 1 recruiting NCT02669771
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule Not Available Not Available completed NCT05549778
Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC treatment 1 / 2 completed NCT02346578
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. treatment 2 completed NCT03960788
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer diagnostic 0 unknown_status NCT01981707
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer No drug interventions diagnostic 2 / 3 terminated NCT06585007
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer No drug interventions treatment 3 recruiting NCT01981109
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer No drug interventions Not Available Not Available terminated NCT04070209
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) treatment 2 recruiting NCT04148885
A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer treatment 1 / 2 unknown_status NCT04838899
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer No drug interventions treatment Not Available recruiting NCT03261336
Oral Calcitriol With Ketoconazole in CRPC treatment 2 terminated NCT03514836
A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer treatment 1 / 2 terminated NCT05585034
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors treatment 1 recruiting NCT04102124
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC treatment 2 unknown_status NCT03658486
Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial No drug interventions other Not Available completed NCT02361086
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer treatment 1 / 2 completed NCT05501548
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer treatment 2 recruiting NCT03381326
CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC. No drug interventions Not Available Not Available active_not_recruiting NCT06378866
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial treatment 2 recruiting NCT02380274
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) No drug interventions Not Available Not Available completed NCT04019327
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer treatment 1 / 2 active_not_recruiting NCT03526562
Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients No drug interventions treatment Not Available completed NCT03939689
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone treatment 2 active_not_recruiting NCT06251492
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) treatment 2 recruiting NCT03356444
Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate treatment 2 unknown_status NCT06228404
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC No drug interventions treatment 0 recruiting NCT02124668
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy treatment 2 completed NCT03101046
Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic treatment 2 completed NCT05534646
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer treatment 2 recruiting NCT03741712
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC treatment 1 / 2 terminated NCT03247010
Bone Marrow Suppression and Recovery During Radionuclide Treatment No drug interventions Not Available Not Available completed NCT03850795
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment 3 terminated NCT04839055
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC treatment 1 / 2 unknown_status NCT02925702
PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223. Not Available Not Available unknown_status NCT02922218
PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide. No drug interventions Not Available Not Available unknown_status NCT02669147
A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC No drug interventions Not Available Not Available completed NCT01911728
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates treatment 1 completed NCT01534052
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 treatment 2 completed NCT01284920
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients treatment 1 / 2 completed NCT02698176
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) treatment 1 terminated NCT01911741
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects basic_science 1 completed NCT05655715
Checkpoint Inhibitors and SBRT for MCRPC treatment 2 completed NCT05252390
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors treatment 1 / 2 recruiting NCT05488548
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies No drug interventions treatment 1 recruiting NCT01144897
PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy diagnostic 1 completed NCT05766371
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer treatment 2 recruiting NCT04296578
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone treatment 1 withdrawn NCT05627752
Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage treatment 2 / 3 recruiting NCT05582031
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers treatment 2 withdrawn NCT05570994
177Lu-HTK03170 in mCRPC With PSMA Positive Disease treatment 1 / 2 recruiting NCT05156372
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients No drug interventions treatment Not Available withdrawn NCT04995614
Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223 Not Available Not Available completed NCT06527690
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer treatment 2 not_yet_recruiting NCT05415098
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas No drug interventions treatment 1 recruiting NCT04319783
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA treatment 2 recruiting NCT01907009
A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) treatment 2 / 3 terminated NCT04737109
Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer treatment 1 / 2 terminated NCT04969315
TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors treatment 1 / 2 active_not_recruiting NCT01313559
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer treatment 2 terminated NCT01832870
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer treatment 1 completed NCT05159518
A Study of PRT2527 in Participants With Advanced Solid Tumors No drug interventions treatment 1 completed NCT06395519
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies No drug interventions treatment 1 recruiting NCT05191017
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC treatment 1 / 2 withdrawn NCT04335682
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide other 2 recruiting NCT01352208
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients No drug interventions treatment 1 / 2 terminated NCT01823978
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer treatment 1 completed NCT04113005
Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer treatment 0 unknown_status NCT00868595
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer treatment 1 completed NCT03419442
Multi-academic Center Study of Xofigo Patients Not Available Not Available completed NCT01083615
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) treatment 3 terminated NCT04053062
LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer No drug interventions treatment 1 suspended NCT00838201
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer treatment 3 completed NCT04768608
PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer No drug interventions treatment 1 completed NCT01717898
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer treatment 1 / 2 terminated NCT01599793
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer diagnostic 2 completed NCT01824342
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer treatment 3 completed NCT01234025
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) treatment 1 / 2 completed NCT00770848
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer treatment 1 / 2 completed NCT02814669
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor treatment 1 completed NCT02259114
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) treatment 1 completed NCT06276465
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging treatment 3 not_yet_recruiting NCT04157088
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) treatment 2 terminated NCT04141709
Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer No drug interventions treatment Not Available recruiting NCT04381832
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer treatment 1 / 2 active_not_recruiting NCT02866916
Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA) No drug interventions treatment 1 withdrawn NCT05519449
Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) No drug interventions treatment 1 recruiting NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT04833517
Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) No drug interventions Not Available Not Available recruiting NCT04337580
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer treatment 2 recruiting NCT03248570
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects treatment 2 completed NCT04918810
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer treatment 2 recruiting NCT05551117
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors treatment 2 active_not_recruiting NCT03748641
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer treatment 3 active_not_recruiting NCT04116164
Safety and Targeting of Anti-hk2 Antibody in mCRPC No drug interventions other 0 terminated NCT04104607
the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma No drug interventions treatment 1 recruiting NCT04126915
Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES) No drug interventions Not Available Not Available not_yet_recruiting NCT05293496
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors treatment 1 recruiting NCT02398526
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases Not Available Not Available completed NCT04404140
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). treatment 1 terminated NCT02998567
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab health_services_research 1 recruiting NCT03016741
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer supportive_care 4 unknown_status NCT06033001
Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Not Available Not Available available